Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr;103(4):e158-e161.
doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Panagiotis Baliakas  1 , Mattias Mattsson  1   2 , Anastasia Hadzidimitriou  3 , Eva Minga  3 , Andreas Agathangelidis  3   4   5 , Lesley-Ann Sutton  1 , Lydia Scarfo  4   5 , Zadie Davis  6 , Xiao-Jie Yan  7 , Karla Plevova  8   9 , Yorick Sandberg  10 , Fie J Vojdeman  11 , Tatiana Tzenou  12 , Charles C Chu  7 , Silvio Veronese  13 , Larry Mansouri  1 , Karin E Smedby  14 , Véronique Giudicelli  15 , Florence Nguyen-Khac  16 , Panagiotis Panagiotidis  12 , Gunnar Juliusson  17 , Achilles Anagnostopoulos  18 , Marie-Paule Lefranc  15 , Livio Trentin  19   20 , Mark Catherwood  21 , Marco Montillo  13 , Carsten U Niemann  11 , Anton W Langerak  10 , Sarka Pospisilova  8   9 , Niki Stavroyianni  18 , Nicholas Chiorazzi  7 , David Oscier  6 , Diane F Jelinek  22 , Tait Shanafelt  23 , Nikos Darzentas  8 , Chrysoula Belessi  24 , Frederic Davi  16 , Paolo Ghia  4   5 , Richard Rosenquist  1   25 , Kostas Stamatopoulos  26   3   18
Affiliations

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy

Panagiotis Baliakas et al. Haematologica. 2018 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival for patients with chronic lymphocytic leukemia in the present cohort. (A) Inferior overall survival (OS) for cases treated between 1980–2005 (blue line) versus cases treated between 2006–2014 (red line). (B) Inferior OS for all U-CLL cases treated between 1980–2005. (C–E) No improvement in OS over time for patients carrying del(17p) (C) or patients belonging to subset #1 (D) or subset #2 (E). (F) No improvement in OS over time for cases belonging to subset #2 even after excluding del(17p) cases.
See this image and copyright information in PMC

References

    1. da Cunha-Bang C, Simonsen J, Rostgaard K, Geisler C, Hjalgrim H, Niemann CU. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients. Blood Cancer J. 2016;6(11):e499. - PMC - PubMed
    1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–1174. - PubMed
    1. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2015;90(5):446–460. - PubMed
    1. Lamanna N, O’Brien S. Novel agents in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2016;2016(1):137–145. - PMC - PubMed
    1. Fabbri G, Dalla-Favera R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat Rev Cancer. 2016;16(3):145–162. - PubMed

Publication types